Compugen’s anti-PVRIG patent upheld by the EPO

Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Illumina ordered to recall products after German patent ruling

16 July 2026 A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

Biotech

Merck KGaA agrees $11.3bn deal in major life sciences expansion

26 June 2026 Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.

More features

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

Compugen’s anti-PVRIG patent upheld by the EPO

More on this story

Editor's picks

Editor's picks

More features